Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Net Income towards Common Stockholders (2018 - 2023)

Historic Net Income towards Common Stockholders for ImmunoTech (AIM) over the last 6 years, with Q4 2023 value amounting to -$14.0 million.

  • ImmunoTech's Net Income towards Common Stockholders changed N/A to -$14.0 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$14.0 million, marking a year-over-year decrease of 2183.75%. This contributed to the annual value of -$20.4 million for FY2024, which is 3621.69% up from last year.
  • Per ImmunoTech's latest filing, its Net Income towards Common Stockholders stood at -$14.0 million for Q4 2023.
  • In the past 5 years, ImmunoTech's Net Income towards Common Stockholders ranged from a high of -$3.3 million in Q3 2020 and a low of -$14.0 million during Q4 2023